Refuge Biotechnologies, a company researching ways to use CRISPR gene editing to make cancer treatment more precise, has raised $25 million in financing to continue work on its preclinical drug pipeline. China-based 3SBio and Sequoia China led the Series B round of investment in the Menlo Park, CA, company. CRISPR-Cas9 technology uses modified versions of […]
Original Article: Refuge Bio Turns to China for $25M Financing of Precision CRISPR R&D